Tina Cascone, MD, PhD, on NSCLC: Phase III Results on Nivolumab, Chemotherapy, and Surgery

October 21, 2023 By The ASCO Post Staff

Tina Cascone, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses new phase III findings from the CheckMate 77T trial of patients with previously untreated resectable stage II–IIIB non–small cell lung cancer (NSCLC). The trial showed clinically meaningful improvement in event-free survival with neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab vs chemotherapy or placebo (Abstract LBA1).

Related Content